Sierra Oncology

Sierra Oncology is a clinical stage drug development company advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. The company's primary drug candidate, momelotinib, which is for the treatment of myelofibrosis. The company is also advancing, SRA737, is a selective, orally bioavailable small molecule inhibitor of Checkpoint kinase 1, a main regulator of cell cycle progression and the DNA Damage Response replication stress response. The company's pipeline also includes SRA141, a selective, orally bioavailable small molecule inhibitor of cell division cycle 7 kinase.
  • TickerSRRA
  • ISINUS82640U1079
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for SRRA

ValuEngine Rating and Forecast Report for SRRA

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kambiz Yazdi
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

ValuEngine Rating and Forecast Report for SRRA

ValuEngine Rating and Forecast Report for SRRA

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kambiz Yazdi
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

ValuEngine Rating and Forecast Report for SRRA

ValuEngine Rating and Forecast Report for SRRA

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kambiz Yazdi
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kambiz Yazdi
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

1 director bought

A director at Sierra Oncology Inc bought 229,000 shares at 0.440USD and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names o...

ValuEngine Rating and Forecast Report for SRRA

ValuEngine Rating and Forecast Report for SRRA

ValuEngine Rating and Forecast Report for SRRA

ValuEngine Rating and Forecast Report for SRRA

ValuEngine Rating and Forecast Report for SRRA

ValuEngine Rating and Forecast Report for SRRA

ValuEngine Rating and Forecast Report for SRRA

ValuEngine Rating and Forecast Report for SRRA

ValuEngine Rating and Forecast Report for SRRA

ValuEngine Rating and Forecast Report for SRRA

ResearchPool Subscriptions

Get the most out of your insights

Get in touch